Pralsetinib’s promise in RET-altered cancers: Blueprint’s $775m deal with Roche

NSCLC is a form of RET-altered cancers that requires improved treatments to target this genetic alteration. Credit: Librepath via Wikimedia.



  • Blueprint Roche